Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques

Vaccine

Volumn 26, Issue 33, 2008, Pages 4224-4230

  Herfst, Sander ^a   Schrauwen, Eefje J A ^a   de Graaf, Miranda ^a   van Amerongen, Geert ^a   van den Hoogen, Bernadette G ^a   de Swart, Rik L ^a   Osterhaus, Albert D M E ^a   Fouchier, Ron A M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fusion protein; Human metapneumovirus; Live attenuated vaccine; Macaque; Subunit vaccine

Indexed keywords

HUMAN METAPNEUMOVIRUS FSO1 SUBUNIT VACCINE; HUMAN METAPNEUMOVIRUS VACCINE; HYBRID PROTEIN; LIVE ATTENUATED HUMAN METAPNEUMOVIRUS VACCINE; LIVE VACCINE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MACACA; METAPNEUMOVIRUS; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS RECOMBINANT; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTES; MACACA FASCICULARIS; METAPNEUMOVIRUS; NEUTRALIZATION TESTS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VIRAL VACCINES; VIRUS SHEDDING;

EID: 47149106807     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.052     Document Type: Article

References (38)

1. van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7 6 (2001) 719-724
2. van den Hoogen B.G., Herfst S., Sprong L., Cane P.A., Forleo E., de Swart R.L., et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 10 4 (2004) 658-666
3. van den Hoogen B.G., van Doornum G.J., Fockens J.C., Cornelissen J.J., Beyer W.E., de Groot R., et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 188 10 (2003) 1571-1577
4. Williams J.V., Wang C.K., Yang C.F., Tollefson S.J., House F.S., Heck J.M., et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 193 3 (2006) 387-395
5. Herfst S., and Fouchier R.A. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol 41 1 (2008) 49-52
6. Cseke G., Wright D.W., Tollefson S.J., Johnson J.E., Crowe Jr. J.E., and Williams J.V. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 81 2 (2007) 698-707
7. Herfst S., de Graaf M., Schrauwen E.J., Ulbrandt N.D., Barnes A.S., Senthil K., et al. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 88 (2007) 2702-2709
8. Biacchesi S., Pham Q.N., Skiadopoulos M.H., Murphy B.R., Collins P.L., and Buchholz U.J. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 79 19 (2005) 12608-12613
9. Tang R.S., Mahmood K., Macphail M., Guzzetta J.M., Haller A.A., Liu H., et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 23 14 (2005) 1657-1667
10. Pham Q.N., Biacchesi S., Skiadopoulos M.H., Murphy B.R., Collins P.L., and Buchholz U.J. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 79 24 (2005) 15114-15122
11. Herfst S., De Graaf M., Schrauwen E.J.A., Sprong L., Hussain K., Van den Hoogen B.G., et al. Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. J Gen Virol 89 (2008) 1553-1562
12. Herd K.A., Mahalingam S., Mackay I.M., Nissen M., Sloots T.P., and Tindle R.W. Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J Virol 80 4 (2006) 2034-2044
13. Hamelin M.E., Couture C., Sackett M.K., and Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol 88 Pt. 12 (2007) 3391-3400
14. de Swart R.L., van den Hoogen B.G., Kuiken T., Herfst S., van Amerongen G., Yuksel S., et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 25 51 (2007) 8518-8528
15. Yim K.C., Cragin R.P., Boukhvalova M.S., Blanco J.C., Hamlin M.E., Boivin G., et al. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 25 27 (2007) 5034-5040
16. Polack F.P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 62 1 (2007) 111-115
17. Fulginiti V.A., Eller J.J., Downie A.W., and Kempe C.H. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202 12 (1967) 1075-1080
18. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 4 (1969) 422-434
19. De Swart R.L., Kuiken T., Timmerman H.H., van Amerongen G., Van Den Hoogen B.G., Vos H.W., et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 76 22 (2002) 11561-11569
20. Hancock G.E., Smith J.D., and Heers K.M. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus. J Infect Dis 181 5 (2000) 1768-1771
21. Murphy B.R., Sotnikov A., Paradiso P.R., Hildreth S.W., Jenson A.B., Baggs R.B., et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7 6 (1989) 533-540
22. Falsey A.R., and Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14 13 (1996) 1214-1218
23. Munoz F.M., Piedra P.A., and Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 24 (2003) 3465-3467
24. Piedra P.A., Cron S.G., Jewell A., Hamblett N., McBride R., Palacio M.A., et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21 19-20 (2003) 2448-2460
25. Tristram D.A., Welliver R.C., Mohar C.K., Hogerman D.A., Hildreth S.W., and Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 167 1 (1993) 191-195
26. Kuiken T., Van Den Hoogen B.G., Van Riel D.A., Laman J.D., Van Amerongen G., Sprong L., et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 164 6 (2004) 1893-1900
27. Herfst S., de Graaf M., Schickli J.H., Tang R.S., Kaur J., Yang C.F., et al. Recovery of human metapneumovirus genetic lineages A and B from cloned cDNA. J Virol 78 15 (2004) 8264-8270
28. Ulbrandt N.D., Ji H., Patel N.K., Riggs J.M., Brewah Y.A., Ready S., et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 80 16 (2006) 7799-7806
29. Bebbington C.R., Renner G., Thomson S., King D., Abrams D., and Yarranton G.T. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (NY) 10 2 (1992) 169-175
30. de Graaf M., Herfst S., Schrauwen E.J., van den Hoogen B.G., Osterhaus A.D., and Fouchier R.A. An improved plaque reduction virus neutralization assay for human metapneumovirus. J Virol Methods 143 2 (2007) 169-174
31. van den Hoogen B.G., Herfst S., de Graaf M., Sprong L., van Lavieren R., van Amerongen G., et al. Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 88 Pt. 4 (2007) 1251-1259
32. Maertzdorf J., Wang C.K., Brown J.B., Quinto J.D., Chu M., De Graaf M., et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 42 3 (2004) 981-986
33. Reed L.J., and Muench H. A simple method of estimating fifty percent end points. J Hygiene 27 (1938) 493-497
34. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., and Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344 6269 (1990) 873-875
35. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., and Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8 5 (1990) 497-502
36. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., and Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 13 4 (1995) 391-400
37. Ebihara T., Endo R., Ishiguro N., Nakayama T., Sawada H., and Kikuta H. Early reinfection with human metapneumovirus in an infant. J Clin Microbiol 42 12 (2004) 5944-5946
38. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Riggs J.M., Surman S.R., Amaro-Carambot E., et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 78 13 (2004) 6927-6937